Greenwich LifeSciences’ $7.25 Million Initial Public Offering


Sichenzia Ross Ference LLP represented Aegis Capital Corp., as a sole bookrunner in the offering.

Greenwich LifeSciences, Inc. (NASDAQ: GSLI) executed its initial public offering of 1,260,870 shares of the common stock. The shares were sold to the public at at a price of $5.75 per share for gross proceeds of approximately $7,250,000.

The shares commenced trading on The Nasdaq Capital Market on September 25, 2020.

Greenwich LifeSciences is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery.

The Sichenzia Ross Ference LLP team representing Aegis Capital was led by Partners Gregory Sichenzia (Picture), Darrin Ocasio, and Avital Perlman, counsel Jeff Cahlon and associate Yian Pan.

Involved fees earner: Jeffrey Cahlon – Sichenzia Ross Ference LLP; Darrin Ocasio – Sichenzia Ross Ference LLP; Yian Pan – Sichenzia Ross Ference LLP; Avital Perlman – Sichenzia Ross Ference LLP; Gregory Sichenzia – Sichenzia Ross Ference LLP;

Law Firms: Sichenzia Ross Ference LLP;

Clients: Aegis Capital Corporation;

Author: Ambrogio Visconti